HFA
ALXN

Hoover Financial Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Hoover Financial Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$6K Hold
35
– – ﹤0.01% 535
2021
Q1 		$6K Buy
+35
New +$5.41K ﹤0.01% 488

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Hoover Financial Advisors's ALXN Position: Q2 2021 in Review

Hoover Financial Advisors held its Alexion Pharmaceuticals (ALXN) position steady in Q2 2021 at 35 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #535.

Hoover Financial Advisors first reported a position in ALXN in Q1 2021 and has held it in 2 quarters since. 708 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Hoover Financial Advisors held 35 shares of Alexion Pharmaceuticals worth $6K as of Q2 2021.
  • Hoover Financial Advisors left its Alexion Pharmaceuticals share count unchanged in Q2 2021.
  • Alexion Pharmaceuticals made up ﹤0.01% of Hoover Financial Advisors's portfolio in Q2 2021, its #535 holding.
  • Hoover Financial Advisors first reported a position in Alexion Pharmaceuticals in Q1 2021 and has held it in 2 quarters since.
  • 708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Hoover Financial Advisors's 13F filing for Q2 2021, filed 28 Jul 2021.